Literature DB >> 31865389

Left ventricular wall thickness assessed by cardiac computed tomography and cardiac resynchronization therapy outcomes.

Vincent Galand1,2, Brian Ghoshhajra3, Jackie Szymonifka4, Saumya Das2, Mary Orencole2, Valentin Barré1, Raphaël P Martins1, Christophe Leclercq1, Judy Hung2, Quynh A Truong5, Jagmeet P Singh2.   

Abstract

AIMS: Up to 30% of selected heart failure patients do not benefit clinically from cardiac resynchronization therapy (CRT). Left ventricular (LV) wall thickness (WT) analysed using computed tomography (CT) has rarely been evaluated in response to CRT and mitral regurgitation (MR) improvement. We examined the association of LVWT and the ability to reverse LV remodelling and MR improvement after CRT. METHODS AND
RESULTS: Fifty-four patients scheduled for CRT underwent pre-procedural CT. Reduced LVWT was defined as WT <6 mm and quantified as a percentage of total LV area. Endpoints were 6-month clinical and echocardiographic response to CRT [New York Heart Association (NYHA) class, LV ejection fraction (LVEF), LV end-diastolic volume (LVEDV), and LV end-systolic volume (LVESV)], MR improvement and 2-year major adverse cardiac events (MACE). Patients were divided into three groups according to the percentage of LVWT <6 mm area: ≤20%, 20-50%, and ≥50%. At 6 months, 75%, 71%, and 42% of the patients experienced NYHA improvement in the ≤20%, 20-50%, and ≥50% group, respectively. Additionally, ≤20% group presented higher LVEF, LVEDV, and LVESV positive response rate (86%, 59%, and 83%, respectively). Both 20-50% and ≥50% groups exhibited a lower LVEF, LVEDV, and LVESV positive response rate (52% and 42%; 47% and 45%; and 53% and 45%, respectively). Additionally, ≥25% of LVWT <6 mm inclusive of at least one papillary muscle insertion was the only predictor of lack of MR improvement. Lastly, ≥50% group experienced significantly lower 2-year MACE survival free probability.
CONCLUSION: WT evaluated using CT could help to stratify the response to CRT and predict MR improvement and outcomes. CLINICAL TRIAL REGISTRATION: NCT01097733. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac resynchronization therapy; Computed tomography; Heart failure; Left ventricular wall thickness; Mitral regurgitation; Outcome; Response to cardiac resynchronization therapy

Mesh:

Year:  2020        PMID: 31865389      PMCID: PMC7058969          DOI: 10.1093/europace/euz322

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  20 in total

1.  Detection of viable myocardium and scar tissue.

Authors:  Jeroen J Bax; Victoria Delgado
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-08-19       Impact factor: 6.875

2.  Computed Tomography-Guided Assessment of Response to Cardiac Resynchronization Therapy.

Authors:  Vincent Galand; Brian Ghoshhajra; Jackie Szymonifka; Christophe Leclercq; Quynh A Truong; Jagmeet P Singh
Journal:  JACC Clin Electrophysiol       Date:  2019-08-19

3.  2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management.

Authors:  Jean-Claude Daubert; Leslie Saxon; Philip B Adamson; Angelo Auricchio; Ronald D Berger; John F Beshai; Ole Breithard; Michele Brignole; John Cleland; David B DeLurgio; Kenneth Dickstein; Derek V Exner; Michael Gold; Richard A Grimm; David L Hayes; Carsten Israel; Christophe Leclercq; Cecilia Linde; JoAnn Lindenfeld; Bela Merkely; Lluis Mont; Francis Murgatroyd; Frits Prinzen; Samir F Saba; Jerold S Shinbane; Jagmeet Singh; Anthony S Tang; Panos E Vardas; Bruce L Wilkoff; Jose Luis Zamorano; Inder Anand; Carina Blomström-Lundqvist; John P Boehmer; Hugh Calkins; Serge Cazeau; Victoria Delgado; N A Mark Estes; David Haines; Fred Kusumoto; Paco Leyva; Frank Ruschitzka; Lynne Warner Stevenson; Christian Tobias Torp-Pedersen
Journal:  Europace       Date:  2012-09       Impact factor: 5.214

4.  Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy.

Authors:  Francisco Leyva; Robin J Taylor; Paul W X Foley; Fraz Umar; Lawrence J Mulligan; Kiran Patel; Berthold Stegemann; Tarek Haddad; Russell E A Smith; Sanjay K Prasad
Journal:  J Am Coll Cardiol       Date:  2012-09-26       Impact factor: 24.094

Review 5.  Applications of cardiac computed tomography in electrophysiology intervention.

Authors:  S Liddy; U Buckley; H K Kok; B Loo; B Glover; G R Dhillon; O Buckley
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2018-03-01       Impact factor: 6.875

6.  Utility of dual-source computed tomography in cardiac resynchronization therapy-DIRECT study.

Authors:  Quynh A Truong; Jackie Szymonifka; Michael H Picard; Wai-Ee Thai; Bryan Wai; Jim W Cheung; E Kevin Heist; Udo Hoffmann; Jagmeet P Singh
Journal:  Heart Rhythm       Date:  2018-03-20       Impact factor: 6.343

7.  Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction.

Authors:  Yitschak Biton; Ilan Goldenberg; Valentina Kutyifa; Jayson R Baman; Scott Solomon; Arthur J Moss; Barbara Szepietowska; Scott McNitt; Bronislava Polonsky; Wojciech Zareba; Alon Barsheshet
Journal:  J Am Coll Cardiol       Date:  2016-01-26       Impact factor: 24.094

8.  Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy.

Authors:  Gabe B Bleeker; Theodorus A M Kaandorp; Hildo J Lamb; Eric Boersma; Paul Steendijk; Albert de Roos; Ernst E van der Wall; Martin J Schalij; Jeroen J Bax
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

9.  Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.

Authors:  Claude Daubert; Michael R Gold; William T Abraham; Stefano Ghio; Christian Hassager; Grahame Goode; Tamás Szili-Török; Cecilia Linde
Journal:  J Am Coll Cardiol       Date:  2009-10-01       Impact factor: 24.094

Review 10.  Patient assessment for cardiac resynchronization therapy: Past, present and future of imaging techniques.

Authors:  D Auger; A Ducharme; F Harel; B Thibault; E O'Meara
Journal:  Can J Cardiol       Date:  2010-01       Impact factor: 5.223

View more
  1 in total

Review 1.  Predictors of persistence of functional mitral regurgitation after cardiac resynchronization therapy: Review of literature.

Authors:  Eleonora Russo; Giulio Russo; Maurizio Braccio; Mauro Cassese
Journal:  World J Cardiol       Date:  2022-03-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.